This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

B8FE Stock Overview

A biopharmaceutical company, engages in the research, development, and distribution of dermatological products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. More details

B8FE fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	5/6
Past Performance	3/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 70.6% below our estimate of its fair value

Earnings are forecast to grow 44.5% per year

Became profitable this year

Risk Analysis

Highly volatile share price over the past 3 months

Large one-off items impacting financial results

Does not have a meaningful market cap (€78M)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Biofrontera AG Competitors

MPH Health Care

DB:93M1

€101.9m

PharmaSGP Holding

XTRA:PSG

€308.5m

Dermapharm Holding

XTRA:DMP

€2.1b

Choong Ang Vaccine Laboratory

KOSDAQ:A072020

₩90.9b

Price History & Performance

Summary of share price highs, lows and changes for Biofrontera
Historical stock prices
Current Share Price	€2.26
52 Week High	€4.74
52 Week Low	€1.26
Beta	1.27
1 Month Change	2.73%
3 Month Change	32.94%
1 Year Change	-48.64%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-80.52%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	B8FE	DE Pharmaceuticals	DE Market
7D	-11.7%	-0.4%	0.9%
1Y	-48.6%	-18.9%	13.2%

Return vs Industry: B8FE underperformed the German Pharmaceuticals industry which returned -7.9% over the past year.

Return vs Market: B8FE underperformed the German Market which returned -25.6% over the past year.

Price Volatility

Is B8FE's price volatile compared to industry and market?
B8FE volatility
B8FE Average Weekly Movement	31.8%
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	6.4%
10% most volatile stocks in DE Market	12.9%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: B8FE's share price has been volatile over the past 3 months.

Volatility Over Time: B8FE's weekly volatility has increased from 26% to 32% over the past year.

About the Company

Founded	Employees	CEO	Website
1997	98	Hermann Lubbert	www.biofrontera.com

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and marketing of dermatological products. Its products include Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also develops RhodoLED XL for the treatment of multiple interspersed lesions; Belixos, a modern active cosmetic product for irritated and sensitive skin; and Xepi for the treatment of antibiotic-resistant bacteria.

Biofrontera AG Fundamentals Summary

How do Biofrontera's earnings and revenue compare to its market cap?
B8FE fundamental statistics
Market cap	€78.27m
Earnings (TTM)	€10.45m
Revenue (TTM)	€30.77m

7.5x

P/E Ratio

2.5x

P/S Ratio

Is B8FE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
B8FE income statement (TTM)
Revenue	€30.77m
Cost of Revenue	€4.67m
Gross Profit	€26.10m
Other Expenses	€15.65m
Earnings	€10.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	0.18
Gross Margin	84.82%
Net Profit Margin	33.95%
Debt/Equity Ratio	0.5%

How did B8FE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/09/22 18:45
End of Day Share Price	2022/09/20 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biofrontera AG is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Raymond Myers	Benchmark Company
Navid Malik	Cavendish Historical (Cenkos Securities)
Robert Wasserman	Dawson James Securities